185
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study

, , , , , , , , , , , , , , , , , , , , , , , , , , & show all
Pages 1563-1567 | Received 11 Jul 2018, Accepted 26 Sep 2018, Published online: 09 Jan 2019
 

Acknowledgments

The authors would like to thank the physicians, patients, and patients’ families that participated in this study.

The authors would also like to thank the study project team and Eltium for the support received in writing and editing this article.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2018.1533130.

Additional information

Funding

The study is funded by Roche, France.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.